BackgroundPD-1/PD-L1 inhibitors combined with chemotherapy have improved survival outcomes in patients with driver mutation–negative non-squamous non-small cell lung cancer (non-sqNSCLC). However, the comparative efficacy, safety, and economic value of available PD-1/PD-L1 inhibitor–based regimens remain uncertain in China.MethodsWe conducted a network meta-analysis to indirectly compare the effi…
